Canada Markets open in 8 hrs 42 mins

Longeveron Inc. (LGVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.08+0.27 (+3.06%)
At close: 04:00PM EST
9.13 +0.05 (+0.55%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close8.81
Open8.46
Bid8.96 x 900
Ask9.13 x 1100
Day's Range8.46 - 9.46
52 Week Range2.84 - 45.00
Volume780,256
Avg. Volume12,843,904
Market Cap189.326M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging

    MIAMI, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed article describes the design of the trial which investigated Lomec

  • GlobeNewswire

    Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease

    Trial designed to obtain safety and efficacy data of single and multiple dosing regimenMIAMI, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participa

  • GlobeNewswire

    Longeveron to Participate in the H.C. Wainwright BioConnect 2022 Virtual Conference

    Longeveron CEO Geoff Green to give presentation and will participate in panel discussion titled “The Emerging Cell & Gene Therapy Landscape—From Hope to Reality” moderated by Dr. Scott Gottlieb, former Commissioner of the FDAMIAMI, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today that Geoff Green, Chief Execu